Terms: = Ovarian cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Treatment
41 results:
1. PIK3R3, a regulatory subunit of PI3K, modulates ovarian cancer stem cells and ovarian cancer development and progression by integrative analysis.
Sohn EJ
BMC Cancer; 2022 Jun; 22(1):708. PubMed ID: 35761259
[TBL] [Abstract] [Full Text] [Related]
2. ROS and miRNA Dysregulation in ovarian cancer Development, Angiogenesis and Therapeutic Resistance.
Stieg DC; Wang Y; Liu LZ; Jiang BH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743145
[TBL] [Abstract] [Full Text] [Related]
3. The Anti-her3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract] [Full Text] [Related]
4. NRG1/erbb3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
[TBL] [Abstract] [Full Text] [Related]
5. erbb3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.
Chen C; Gupta P; Parashar D; Nair GG; George J; Geethadevi A; Wang W; Tsaih SW; Bradley W; Ramchandran R; Rader JS; Chaluvally-Raghavan P; Pradeep S
Oncogene; 2020 Apr; 39(14):2921-2933. PubMed ID: 32029900
[TBL] [Abstract] [Full Text] [Related]
6. Heterogeneous alteration of the erbb3-MYC axis associated with MEK inhibitor resistance in a
Colombo I; Garg S; Danesh A; Bruce J; Shaw P; Tan Q; Quevedo R; Braunstein M; Oza AM; Pugh T; Lheureux S
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31836588
[TBL] [Abstract] [Full Text] [Related]
7. Dual targeting of IGF-1R and erbb3 as a potential therapeutic regimen for ovarian cancer.
Camblin AJ; Tan G; Curley MD; Yannatos I; Iadevaia S; Rimkunas V; Mino-Kenudson M; Bloom T; Schoeberl B; Drummond DC; Lugovskoy AA; Louis CU; Askoxylakis V
Sci Rep; 2019 Nov; 9(1):16832. PubMed ID: 31728045
[TBL] [Abstract] [Full Text] [Related]
8. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (her3) mRNA-expressing platinum-resistant ovarian cancer.
Lorusso D; Hilpert F; González Martin A; Rau J; Ottevanger P; Greimel E; Lück HJ; Selle F; Colombo N; Kroep JR; Mirza MR; Berger R; Pardo B; Grischke EM; Berton-Rigaud D; Martinez-Garcia J; Vergote I; Redondo A; Cardona A; Bastière-Truchot L; du Bois A; Kurzeder C;
Int J Gynecol Cancer; 2019 Sep; 29(7):1141-1147. PubMed ID: 31420414
[TBL] [Abstract] [Full Text] [Related]
9. her3-Targeted Affibodies with Optimized Formats Reduce ovarian cancer Progression in a Mouse Xenograft Model.
Schardt JS; Noonan-Shueh M; Oubaid JM; Pottash AE; Williams SC; Hussain A; Lapidus RG; Lipkowitz S; Jay SM
AAPS J; 2019 Apr; 21(3):48. PubMed ID: 30949858
[TBL] [Abstract] [Full Text] [Related]
10. Response to erbb3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
11. miR-152 is involved in the proliferation and metastasis of ovarian cancer through repression of erbb3.
Li LW; Xiao HQ; Ma R; Yang M; Li W; Lou G
Int J Mol Med; 2018 Mar; 41(3):1529-1535. PubMed ID: 29286064
[TBL] [Abstract] [Full Text] [Related]
12. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
Momeny M; Zarrinrad G; Moghaddaskho F; Poursheikhani A; Sankanian G; Zaghal A; Mirshahvaladi S; Esmaeili F; Eyvani H; Barghi F; Sabourinejad Z; Alishahi Z; Yousefi H; Ghasemi R; Dardaei L; Bashash D; Chahardouli B; Dehpour AR; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Jun; 7(1):4204. PubMed ID: 28646172
[TBL] [Abstract] [Full Text] [Related]
13. Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.
Corno C; Gatti L; Arrighetti N; Carenini N; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2017 Jul; 136():40-50. PubMed ID: 28404378
[TBL] [Abstract] [Full Text] [Related]
14. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory ovarian cancer.
Liu JF; Ray-Coquard I; Selle F; Poveda AM; Cibula D; Hirte H; Hilpert F; Raspagliesi F; Gladieff L; Harter P; Siena S; Del Campo JM; Tabah-Fisch I; Pearlberg J; Moyo V; Riahi K; Nering R; Kubasek W; Adiwijaya B; Czibere A; Naumann RW; Coleman RL; Vergote I; MacBeath G; Pujade-Lauraine E
J Clin Oncol; 2016 Dec; 34(36):4345-4353. PubMed ID: 27998236
[TBL] [Abstract] [Full Text] [Related]
15. ovarian Function, Not Age, Predicts the Benefit from ovarian Suppression or Ablation for Premenopausal Women with Breast cancer.
Xue C; Peng R; Cao Y; Wang S; Shi Y; An X; Xu F; Yuan Z
PLoS One; 2016; 11(2):e0148849. PubMed ID: 26866810
[TBL] [Abstract] [Full Text] [Related]
16. Role of erbb3 receptors in cancer therapeutic resistance.
Lee Y; Ma J; Lyu H; Huang J; Kim A; Liu B
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):190-8. PubMed ID: 24449784
[TBL] [Abstract] [Full Text] [Related]
17. Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis.
He J; Jing Y; Li W; Qian X; Xu Q; Li FS; Liu LZ; Jiang BH; Jiang Y
PLoS One; 2013; 8(2):e56647. PubMed ID: 23437196
[TBL] [Abstract] [Full Text] [Related]
18. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.
Kaye SB; Poole CJ; Dańska-Bidzińska A; Gianni L; Del Conte G; Gorbunova V; Novikova E; Strauss A; Moczko M; McNally VA; Ross G; Vergote I
Ann Oncol; 2013 Jan; 24(1):145-52. PubMed ID: 23002282
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of doxorubicin-induced her3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Bezler M; Hengstler JG; Ullrich A
Mol Oncol; 2012 Oct; 6(5):516-29. PubMed ID: 22841590
[TBL] [Abstract] [Full Text] [Related]
20. Association between growth factor heregulin1α and receptors in growth of ovarian cancer cell line with high potentiality of peritoneal dissemination.
Nishiyama H; Soeda S; Watanabe T; Fujimori K
Fukushima J Med Sci; 2012; 58(1):22-32. PubMed ID: 22790889
[TBL] [Abstract] [Full Text] [Related]
[Next]